BFM
ALDX icon

Boothbay Fund Management’s Aldeyra Therapeutics ALDX Stock Holding History

Boothbay Fund Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-60,100
Closed -$528K – 1829
2021
Q3 		$528K Buy
+60,100
New +$552K 0.01% 1062
2019
Q2 		– Sell
-470
Closed -$424K – 718
2019
Q1 		$424K Buy
+470
New +$3.99K 0.04% 419
2018
Q4 		– Sell
-318
Closed -$439K – 646
2018
Q3 		$439K Buy
+318
New +$2.58K 0.04% 403

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Boothbay Fund Management's ALDX Position: Q2 2023 in Review

Boothbay Fund Management sold out of Aldeyra Therapeutics (ALDX) in Q2 2023, closing a stake of 16,521 shares — an estimated $164K sold.

Boothbay Fund Management first reported a position in ALDX in Q4 2018 and held it in 9 quarters. The position peaked at $1.24M in Q1 2019. 119 funds tracked by Wall St. Rank hold ALDX as of Q2 2023.

  • Boothbay Fund Management reported no remaining Aldeyra Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 16,521 Aldeyra Therapeutics shares in Q2 2023, an estimated $164K.
  • Boothbay Fund Management first reported a position in Aldeyra Therapeutics in Q4 2018 and held it in 9 quarters.
  • Boothbay Fund Management's Aldeyra Therapeutics position peaked at $1.24M in Q1 2019.
  • 119 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2023.

Based on Boothbay Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.